Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
Standigm
Employs deep learning workflows to streamline early-stage drug discovery projects.
What they do
Standigm develops workflow AI products that automate drug discovery from target identification to lead optimization. Pharmaceutical developers use the company's proprietary platforms, Standigm ASK and Standigm BEST, to rapidly generate novel molecular structures and identify repurposing candidates.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Seoul, South Korea
- Region
- Asia-Pacific
- Founded
- 2015
- Total funding
- $68M raised
Notable investors: Kakao Ventures, SoftBank Ventures Asia, LB Investment, Atinum Investment.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA